Regeneron highlights disease control potential of cemdisiran in gMG

Regeneron's Cemdisiran Monotherapy Shows Strong Efficacy in gMG Phase 3

Regeneron's Phase III NIMBLE study (NCT05070858) demonstrated positive topline data for cemdisiran in generalized myasthenia gravis (gMG). The trial met its primary endpoint, showing a significant change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) at week 24, along with key secondary endpoints. Cemdisiran monotherapy achieved robust efficacy, with a -4.5 change in MG-ADL and -4.2 in Quantitative Myasthenia Gravis (QMG) score, and was generally well-tolerated. The combination with pozelimab showed no additional benefit. Cemdisiran, an RNA interference therapeutic, offers a novel mechanism of action and potential to address the unmet need in LRP4+ gMG patients.

• Robust Efficacy and Safety Profile of Cemdisiran Monotherapy: The Phase III NIMBLE study demonstrated significant clinical improvements with cemdisiran monotherapy, achieving a -4.5 change in MG-ADL and -4.2 change in QMG scores at week 24. These improvements were rapid and sustained throughout the 24-week period. The drug was generally well-tolerated, with no serious infections reported, indicating a favorable safety profile for standalone use.
• Addressing Unmet Needs in LRP4+ gMG Patients: Cemdisiran's promising results in patients who are acetylcholine receptor antibody-positive (AChR+) and/or low-density lipoprotein receptor-related protein 4-positive (LRP4+) are particularly significant. There is a substantial unmet need for effective disease-modifying treatments specifically targeting the LRP4+ gMG population, which cemdisiran monotherapy is well-positioned to address with its novel mechanism of action.
• Strategic Implications for Combination Therapy and Market Positioning: The trial found no additional therapeutic benefit from the cemdisiran + pozelimab combination over cemdisiran monotherapy. This finding has critical implications for Regeneron's commercial strategy and its alliance with Alnylam. Despite this, the combination therapy is still projected to drive substantial sales, estimated at $1.9 billion by 2034, by targeting multiple gMG subtypes.

NIMBLE Study: Cemdisiran's Efficacy and Safety in gMG

Recent clinical investigation in generalized myasthenia gravis (gMG) has yielded meaningful data across several novel therapeutic modalities, spanning FcRn antagonists, dual B-cell survival factor inhibitors, complement inhibitors, and emerging cellular therapies. The studies below represent a cross-section of recent real-world and interventional evidence informing the evolving treatment landscape.

• Multicenter Real-World Efgartigimod Study (2025): Across 46 patients treated at seven tertiary centers over 193 cycles (mean 4.3 per patient), efgartigimod demonstrated an 86.9% rate of ≥2-point MG-ADL improvement following the first cycle, with 52.2% achieving minimal symptom expression (MSE) at least once during follow-up. Among 29 patients on prednisone, 58.6% achieved significant dose reduction (30.9 to 16.8 mg/day; p=0.001). Adverse events occurred in 21.7% of patients, were generally mild, and led to discontinuation in only one case; 35.9% discontinued due to insufficient efficacy, underscoring heterogeneous durability of response.

• Efgartigimod in New-Onset AChR-gMG (2025): In 57 patients receiving efgartigimod combined with oral steroid and immunosuppressive therapy versus 30 receiving conventional treatment, MSE responders (MG-ADL score 0 or 1 sustained >4 weeks) were significantly higher in the efgartigimod arm at 12 weeks (45.61% vs. 13.33%; p=0.0026). Patients with late-onset gMG demonstrated greater MG-ADL reductions than those with thymoma-associated disease (7.06±3.25 vs. 4.96±3.40; p=0.040).

• Efgartigimod in Naive AChR-Ab+ gMG — Immunological Profiling Study (2025): In 17 treatment-naive patients, all achieved clinical improvement alongside significant reductions in serum total IgG and AChR antibody levels. Neutrophil and leukocyte counts peaked at Week 3 (p<0.05), CD4+ and CD8+ T cells transiently decreased at Week 2, and plasmablast proportions significantly increased at Week 2 (p<0.05), with a transient increase in regulatory T cells at Week 1 (p<0.05), providing mechanistic insight into efgartigimod's immunological footprint.

• Efgartigimod in Juvenile MG (JMG) (2025): In 17 patients under 18 years of age, clinically meaningful improvement was observed in 70.6% at Week 1, 73% at Week 2, and 91.7% at Week 4. MG-ADL and QMG scores decreased by 87.6% and 71.8%, respectively, by Week 4 compared to baseline. No treatment-related adverse events were reported in this pediatric cohort.

• Efgartigimod Add-on in Myasthenic Crisis (2026): A retrospective pilot study at the First Affiliated Hospital of Sun Yat-sen University (August 2023–May 2024) compared 9 myasthenic crisis (MC) patients receiving add-on efgartigimod (20 mg/kg on Days 1 and 5) against 14 receiving traditional immunotherapy. Patients in the efgartigimod group reached minimal symptom expression (MSE) more rapidly (p=0.0499), and three patients managed exclusively with high-dose efgartigimod all achieved favorable outcomes. Differences in total hospital stay, mechanical ventilation duration, and MG-ADL trajectories did not reach statistical significance (p>0.05).

• Telitacicept Bayesian Real-World Study (2026): Among 15 evaluable gMG patients (≥12 weeks of treatment), 80.0% met the composite efficacy endpoint (≥2-point MG-ADL and ≥3-point QMG reduction). Mean MG-ADL decreased from 8.0±4.4 to 4.2±3.1 (p<0.01) and mean QMG from 13.8±5.5 to 7.6±4.3 (p<0.01). Mean daily prednisone was reduced by 76.0% (p<0.05), with 3 patients achieving complete withdrawal. Bayesian analysis yielded a posterior mean efficacy rate of 66.67% (95% CrI: 49.99–81.43%), with 97.49% probability of exceeding 50% efficacy. Only mild, transient adverse events occurred; no serious adverse events were reported.

• Telitacicept in Refractory AChR+ gMG (2026): In 42 patients with refractory AChR+ gMG (MGFA class II–IV), telitacicept produced significant improvements in QMG total score (LS mean change at Month 5: −2.24; 95% CI −3.34 to −1.15; p<0.001), with sustained benefits across ocular, limb, and bulbar domains. Cumulative response rates reached 69.9% for MGFA-PIS and 73.8% for QMG improvement (≥3-point reduction) by 6 months. Prednisone was meaningfully reduced (LS mean −10.17 mg/day; p<0.001), and the safety profile was described as promising.

• Eculizumab Retrospective Multi-Center Cohort Study (2025): Across 33 patients (1 EOMG, 13 LOMG, 19 TAMG), eculizumab produced a mean MG-ADL decrease of 7.97±3.96 points and a QMG decrease of 12.88±5.82 points at Week 12, with 78.7% classified as ADL responders and 40% achieving MSE. Benefit was sustained at 24 weeks, with mean prednisone reduced by 12.84±20.36 mg/day. QMG improvement was most pronounced in ocular (66%) and bulbar (49%) muscle groups. No meningococcal infections were recorded; TAMG and myasthenic crisis were identified as particularly suitable indications.

• CAR T-Cell Therapy Case Series Review (2026): A review of five independent case series encompassing seven gMG patients treated with CAR T-cells targeting CD19, BCMA, or bispecific antigens demonstrated consistent clinical improvement across all patients. Peak CAR T-cell expansion occurred 8–22 days post-infusion with persistence of 28 to approximately 180 days. The safety profile was favorable relative to oncology applications, with predominantly Grade 1–2 cytokine release syndrome, rare immune effector cell-associated neurotoxicity, and no severe or life-threatening events. Seven registered trials enrolling over 260 patients are expected to conclude between 2026 and 2029.

Addressing the Unmet Need in LRP4+ gMG Patients

Generalized myasthenia gravis (gMG) continues to carry a substantial clinical and economic burden, with significant gaps remaining in the management of high-risk and treatment-resistant patient populations. Recent literature highlights that standard-of-care therapies — acetylcholinesterase inhibitors, corticosteroids, and immunosuppressants — address only a portion of the disease burden, leaving a meaningful subset of patients inadequately controlled and at elevated risk for severe outcomes.

• Refractory and treatment-resistant patients: Approximately 10–20% of gMG patients are refractory to conventional therapy, and up to 15% exhibit limited or no response to standard treatments. Roughly 20% show poor response to steroids and nonsteroidal immunosuppressive therapies (NSISTs), and only 60–70% of patients achieve disease control with immunosuppressive regimens overall — underscoring a persistent efficacy gap in current therapeutic paradigms.

• High-risk clinical subpopulations: Patients with a history of myasthenic crisis (MC) carry significantly elevated mortality risk compared to those without (54.0 vs. 17.9 per 1,000 person-years; HR 2.33; 95% CI 1.87–2.89). MuSK-MG patients — predominantly female, with pathogenic IgG4 autoantibodies — represent a distinct subgroup with poor long-term outcomes, as only 26.92% achieve clinical remission and no further clinical improvement or reduction in MuSK IgG4 is typically observed beyond four years post-onset. Late-onset MG (LOMG) patients and the growing cohort of elderly individuals with long-term disease represent an additional underserved population requiring more targeted investigation.

• Humanistic and quality-of-life burden: Greater disease severity is consistently associated with reduced quality of life and poorer mental health. Key patient-reported unmet needs include inadequate symptom control, fatigue, dissatisfaction with current treatment, and a strong preference for achieving stable disease. Patients also express a preference for autonomy through self-administered medications at home over infusion-based regimens.

• Long-term treatment toxicity: Standard immunosuppressive therapies carry considerable long-term adverse effect burdens, including increased infection risk, osteoporosis, and diabetes. Current treatments lack target specificity and pose substantial risks for patients requiring chronic immunosuppression, driving the need for more selective, rapid-acting, and safer therapeutic alternatives.

• Access and care delivery gaps: Many patients experience delayed diagnosis, difficulty accessing specialist care, and meaningful communication disconnects with healthcare professionals. In high-burden tuberculosis settings, LTBI screening requirements prior to immunosuppressive therapy introduce additional barriers, with an LTBI frequency of 35.0% identified in one MG cohort, with male and elderly patients disproportionately affected.

• Economic burden: The financial impact of gMG is substantial and escalating with disease severity and comorbidity. Mean incremental healthcare costs for gMG patients in the US were $5,567 versus $1,411 for non-MG comparators, driven primarily by inpatient costs ($2,617 vs. $452). Monthly costs rose to $6,660 in patients with cardiometabolic comorbidities (+20%), $7,443 in those with psychiatric comorbidities (+34%), and $17,330 in patients experiencing acute MG exacerbation or crisis — more than three times baseline. Total annual societal costs in Norway reached EUR 24,743 per patient (2024 data).

• Uncertainty in treatment sequencing: A critical operational gap exists in clinical decision-making: it remains unclear when and in whom to initiate newer therapeutic agents, and how best to integrate them into the evolving treatment paradigm — particularly for clinically unstable patients who may benefit from fast-acting agents as bridge therapy.

Cemdisiran's Strategic Positioning in a Competitive gMG Market

Recent clinical investigation in generalized myasthenia gravis (gMG) has shifted substantially toward evaluating novel biologics both as add-on therapies to standard-of-care (SOC) and in dual-mechanism combination regimens. The most structurally distinctive trial is the phase 3 NIMBLE study, which evaluated cemdisiran — a siRNA targeting complement component C5 — in combination with pozelimab, a C5 monoclonal antibody, across 86 centres in 13 countries. Among 284 randomised patients with anti-AChR or anti-LRP4 seropositive gMG and an MG-ADL score ≥6, the combination arm (cemdisiran 200 mg plus pozelimab 200 mg subcutaneously every 4 weeks) demonstrated a placebo-adjusted least-squares mean difference in MG-ADL score of −1.7 (95% CI: −3.0 to −0.4; p=0.0086) at week 24, with a generally well-tolerated safety profile and no deaths during the double-blind treatment period. Nipocalimab, an FcRn inhibitor, was similarly evaluated as an add-on to SOC in the phase 3 Vivacity-MG3 study, where it produced significantly higher rates of Meaningful Clinical Improvement (MG-ADL ≥2-point), Substantial Improvement (≥3-point), and Considerable Improvement (≥4-point) sustained for ≥12 consecutive weeks versus placebo. Participants receiving nipocalimab were 4-fold more likely to achieve Minimal Symptom Expression (MG-ADL 0 or 1) sustained for ≥8 consecutive weeks (p=0.022), with a composite response odds ratio of 6.3, and improvements emerging as early as week 1.

Efgartigimod, another FcRn inhibitor, has generated meaningful real-world combination data. In a study of 27 AChR-Ab-positive gMG patients treated over 130 treatment cycles, baseline MG-ADL scores decreased by 2.96 points by cycle 2 (p<0.001), reaching a maximum reduction of 3.95 points by cycle 6; severe impairment (MG-ADL ≥10) was eliminated by cycle 5. A clinically significant corticosteroid-sparing effect emerged by cycle 3 (p=0.023), with mean daily methylprednisolone doses falling from 5.8 mg at baseline to 2.3 mg by cycle 5. A separate prospective 26-week study in 41 gMG patients corroborated these findings, showing that the proportion requiring >16 mg/day methylprednisolone decreased from 63.4% at baseline to 14.6% by week 26, with bulbar and respiratory symptoms responding within two weeks and ocular and limb weakness requiring longer treatment durations. A meta-analysis of 29 studies encompassing 1,594 patients further reported that 83% of efgartigimod-treated patients achieved clinically meaningful improvement (≥2-point MG-ADL reduction), with an overall MG-ADL reduction of −4.3 points (95% CI: −4.99 to −3.61).

Beyond complement and FcRn-targeted approaches, telitacicept — a fusion protein targeting BAFF and APRIL — has been used as both monotherapy and combination therapy in patients with ocular myasthenia gravis who failed or were intolerant to standard treatments, yielding marked reductions in MGFA-QMG and MG-ADL scores alongside an initial decline in CD19 B lymphocyte counts and AChR antibody levels, though antibody levels subsequently rebounded despite sustained clinical control. The 2025 Association of British Neurologists (ABN) guidelines have also formalised combination approaches at the institutional level, endorsing daily corticosteroid regimens over alternate-day dosing, early thymectomy, and — supported by randomised controlled trial evidence — early rituximab initiation within one year of generalised disease onset, with acknowledged utility extending to established treatment-refractory cases. Therapeutic plasma exchange continues to be used adjunctively with immunosuppressive or immunomodulatory agents, with emerging interest in immunoadsorption and targeted biologics as complementary strategies.

A New Horizon for gMG Treatment

The positive Phase III NIMBLE study results for Regeneron's cemdisiran represent a pivotal moment for patients living with generalized myasthenia gravis (gMG) and for the broader complement inhibitor market. Cemdisiran, an RNA interference therapeutic, offers a distinct approach by silencing C5 expression directly in the liver, leading to robust and sustained complement suppression. This mechanism, coupled with a convenient subcutaneous quarterly dosing schedule, could significantly enhance patient adherence and quality of life, addressing a critical unmet need in chronic disease management.

The trial's success, demonstrating significant improvements in MG-ADL and QMG scores with cemdisiran monotherapy, positions it as a strong contender against established C5 inhibitors. However, the study also revealed that combining cemdisiran with pozelimab, another C5 inhibitor, did not yield additional clinical benefit in gMG. This finding suggests that while combination strategies might be explored in other complement-mediated conditions, cemdisiran's standalone efficacy is sufficient for gMG, potentially simplifying future treatment paradigms for this indication.

Looking ahead, while the safety profile was generally well-tolerated, the class-wide risk of meningococcal infection associated with C5 inhibition remains a consideration, necessitating robust vaccination strategies. Furthermore, the reported post-treatment deaths, including one deemed investigator-related, will require careful scrutiny during regulatory review. Despite these considerations, the emergence of a highly effective, infrequently dosed, liver-targeting RNAi therapeutic for gMG underscores the continued innovation in precision medicine and offers renewed hope for patients seeking more convenient and impactful treatment options. This development solidifies Regeneron's presence in the complement space, potentially paving the way for cemdisiran's application in other complement-driven pathologies.